Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells
Glushakow-Smith, S. G.; Kaur, I.; Sidoli, S.; Hemmati, S.; Angeles, E.; Sinclair, T.; Chakraborty, S.; Battle, A.; Ames, K.; Narayanagari, S.-R.; Hyka, R.; Soto, M.; Tracy, M.; Vankudoth, J.; Kitamura, S.; Miles, L. A.; Steidl, U.; Shastri, A.; Verma, A.; Gritsman, K.
Show abstract
Acquired non-genetic resistance mechanisms to existing therapies contribute to poor outcomes for acute myeloid leukemia (AML) patients, and inability to target leukemic stem cells (LSCs) can lead to relapse. To overcome these challenges, we tested whether LSCs have dependencies on PI3 kinase (PI3K). We found that LSCs are susceptible to isoform-selective targeting of PI3K and are particularly dependent on the P110 alpha isoform of PI3K. We discovered that PI3K inactivation leads to dynamic changes in EZH2/PRC2 function in leukemic cells, and we uncovered downregulation of EZH2 protein levels as a resistance mechanism in response to PI3K inhibition. We found that PI3K inhibition in AML cells can lead to compensatory upregulation of EZH1, and that EZH1 knockdown can sensitize AML cells to PI3K inhibition. We leveraged this resistance mechanism by combining a PI3K inhibitor with an EZH1/2 dual inhibitor, which successfully overcomes the acquired resistance and leads to sustained targeting of AML cells ex vivo and in murine AML and PDX models in vivo. This study identifies a promising novel therapeutic regimen for targeting LSCs in AML.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Base edited "universal" donor CAR T cell strategies for acute myeloid leukaemia 96%
- Nanoparticle-mediated Targeting of the Fusion Gene RUNX1/ETO in t(8;21)-positive Acute Myeloid Leukaemia 96%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 96%
Similar papers in this journal
- Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation 96%
- Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia 95%
- Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells 94%
Similar papers in this journal
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 96%
- Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms 96%
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 96%
Similar papers in this journal
Similar papers in this journal
- A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity 96%
- The STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Acute Myeloid Leukemia Cells 95%
- Aberrant MNX1 Expression Associated with t(7;12)(q36;p13) Pediatric Acute Myeloid 1 Leukemia Induces the Disease Through Altering Histone Methylation 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.